Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease
Laura Bannach Jardim(Universidade Federal do Rio Grande do Sul), Jéfferson Becker(Hospital de Clínicas de Porto Alegre), Maira Graeff Burin(Hospital de Clínicas de Porto Alegre), Daniel Bocchese Nora(Hospital de Clínicas de Porto Alegre), Luciane Kalakun(Hospital de Clínicas de Porto Alegre), Roberto Giugliani(Universidade Federal do Rio Grande do Sul), Fábio Pereira(Universidade Federal de Alfenas), Ursula S. Matte(Hospital de Clínicas de Porto Alegre), Cristina Brinckmann Oliveira Netto(Universidade Federal do Rio Grande do Sul), Irênio Gomes(Hospital de Clínicas de Porto Alegre)
Cited by 26
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
|Journal of Inherited Metabolic Disease|2011|302
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
|Molecular Genetics and Metabolism|2008|216
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study
|Journal of Inherited Metabolic Disease|2014|211